JP7503380B2 - Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 - Google Patents
Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 Download PDFInfo
- Publication number
- JP7503380B2 JP7503380B2 JP2019536863A JP2019536863A JP7503380B2 JP 7503380 B2 JP7503380 B2 JP 7503380B2 JP 2019536863 A JP2019536863 A JP 2019536863A JP 2019536863 A JP2019536863 A JP 2019536863A JP 7503380 B2 JP7503380 B2 JP 7503380B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methyl
- decan
- azaspiro
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims description 272
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 title claims description 203
- 239000003814 drug Substances 0.000 title claims description 36
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title claims 9
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title claims 9
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical group CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 314
- 239000008194 pharmaceutical composition Substances 0.000 claims description 279
- 206010028980 Neoplasm Diseases 0.000 claims description 277
- 229940000425 combination drug Drugs 0.000 claims description 257
- 201000011510 cancer Diseases 0.000 claims description 241
- 229960001602 ceritinib Drugs 0.000 claims description 184
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 142
- 150000003839 salts Chemical class 0.000 claims description 131
- 238000011282 treatment Methods 0.000 claims description 49
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 31
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 29
- 206010029260 Neuroblastoma Diseases 0.000 claims description 23
- 239000003937 drug carrier Substances 0.000 claims description 22
- 208000020816 lung neoplasm Diseases 0.000 claims description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 20
- 201000005202 lung cancer Diseases 0.000 claims description 20
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 12
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims description 12
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims description 12
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 12
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 206010038389 Renal cancer Diseases 0.000 claims description 12
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 12
- 206010017758 gastric cancer Diseases 0.000 claims description 12
- 201000010982 kidney cancer Diseases 0.000 claims description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 12
- 201000002528 pancreatic cancer Diseases 0.000 claims description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 12
- 201000011549 stomach cancer Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 11
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 11
- 201000004101 esophageal cancer Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 8
- XNRBIYGXCHMMLM-SWLSCSKDSA-N 6-amino-2-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-3-methylpyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=NC(N)=C(C(=O)N1C)C1=CC=CC(Cl)=C1Cl XNRBIYGXCHMMLM-SWLSCSKDSA-N 0.000 claims description 7
- JZDGMMPURNKFOD-UHFFFAOYSA-N NC=1C(=NC=C(N=1)N1CCC(CC1)(C)N)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)C=CC=C2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC(CC1)(C)N)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)C=CC=C2)O)Cl JZDGMMPURNKFOD-UHFFFAOYSA-N 0.000 claims description 7
- VCACXGULTWUFOL-CMPLNLGQSA-N (2R,4R)-4-amino-8-[6-amino-5-(2,3-dichloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-2-ol Chemical compound N[C@@H]1C[C@H](O)CC11CCN(CC1)C1=NC(N)=C(SC2=CC=NC(Cl)=C2Cl)N=C1 VCACXGULTWUFOL-CMPLNLGQSA-N 0.000 claims description 6
- QRCMRHHVLLNDAD-WCQYABFASA-N (2R,4R)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(C[C@H](C[C@H]2N)C)CC1)SC1=C(C(=NC=C1)N)Cl QRCMRHHVLLNDAD-WCQYABFASA-N 0.000 claims description 6
- VCACXGULTWUFOL-ZYHUDNBSSA-N (2S,4R)-4-amino-8-[6-amino-5-(2,3-dichloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-2-ol Chemical compound N[C@@H]1C[C@@H](O)CC11CCN(CC1)C1=NC(N)=C(SC2=CC=NC(Cl)=C2Cl)N=C1 VCACXGULTWUFOL-ZYHUDNBSSA-N 0.000 claims description 6
- NIQAQDPFKXLLSZ-MEDUHNTESA-N (3S,4S)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=NC=CC(=C1Cl)SC=1N=CC(=NC=1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1 NIQAQDPFKXLLSZ-MEDUHNTESA-N 0.000 claims description 6
- ZGMUIFZUVXWGJL-MGPLVRAMSA-N (3S,4S)-8-[5-(6-amino-2,3-dichloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(Cl)=NC(N)=C3)C=N2)[C@@H]1N ZGMUIFZUVXWGJL-MGPLVRAMSA-N 0.000 claims description 6
- MQHUNAGZKZJLQU-APPDUMDISA-N (3S,4S)-8-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C1=C(C(=CC=C1)Cl)Cl MQHUNAGZKZJLQU-APPDUMDISA-N 0.000 claims description 6
- BSPKRXNBXSLYTO-XHDPSFHLSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-ethyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2([C@@H]([C@@H](OC2)CC)N)CC1)SC1=C(C(=NC=C1)N)Cl BSPKRXNBXSLYTO-XHDPSFHLSA-N 0.000 claims description 6
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 claims description 6
- OVNZJLIYRSOHHB-RGUGMKFQSA-N (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound CC1CCC2(CCN(CC2)C2=CN=C(SC3=CC=NC(N)=C3Cl)C=N2)[C@@H]1N OVNZJLIYRSOHHB-RGUGMKFQSA-N 0.000 claims description 6
- CQASZSQCUYWGME-CYBMUJFWSA-N (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=NC=CC(=C1Cl)SC=1N=CC(=NC=1)N1CCC2(CCC[C@H]2N)CC1 CQASZSQCUYWGME-CYBMUJFWSA-N 0.000 claims description 6
- AHSZEDCSMMKDNF-GFCCVEGCSA-N (4S)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound N[C@@H]1COCC11CCN(CC1)C1=CN=C(SC2=CC=NC(N)=C2Cl)C=N1 AHSZEDCSMMKDNF-GFCCVEGCSA-N 0.000 claims description 6
- OMJHHTRDBKAMSN-LLVKDONJSA-N (4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound N[C@@H]1COCC11CCN(CC1)C1=CN=C(SC2=CC=NC(N)=C2Cl)C(N)=N1 OMJHHTRDBKAMSN-LLVKDONJSA-N 0.000 claims description 6
- BXVJYYGWZPCIII-YVEFUNNKSA-N 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(3-chloro-2-methoxypyridin-4-yl)-3-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1N(C(C2=C(N=1)NC=C2C1=C(C(=NC=C1)OC)Cl)=O)C)C BXVJYYGWZPCIII-YVEFUNNKSA-N 0.000 claims description 6
- HZDHVNNLNPUGCB-UHFFFAOYSA-N 2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-(2,3-dichlorophenyl)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound NCC1(CCN(CC1)C=1NC(C2=C(N=1)NC=C2C1=C(C(=CC=C1)Cl)Cl)=O)C HZDHVNNLNPUGCB-UHFFFAOYSA-N 0.000 claims description 6
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical group NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 claims description 6
- URUPFUYPXLMTMT-KPZWWZAWSA-N 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-[3-chloro-2-(cyclopropylamino)pyridin-4-yl]-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C[C@@H]1OCC2(CCN(CC2)c2nc3n[nH]c(-c4ccnc(NC5CC5)c4Cl)c3c(=O)n2C)[C@@H]1N URUPFUYPXLMTMT-KPZWWZAWSA-N 0.000 claims description 6
- JLWLVSCZOWTUQJ-CYBMUJFWSA-N 6-[(4R)-4-amino-2,2-difluoro-8-azaspiro[4.5]decan-8-yl]-3-(6-amino-2-methylpyridin-3-yl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound NC1=CC=C(C(=N1)C)C=1NN=C2N=C(N(C(C2=1)=O)C)N1CCC2(CC(C[C@H]2N)(F)F)CC1 JLWLVSCZOWTUQJ-CYBMUJFWSA-N 0.000 claims description 6
- AWCUGJTVKPBYHS-CQSZACIVSA-N 6-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1N(C(C=2C(N=1)=NNC=2C1=C(C(=CC=C1)Cl)Cl)=O)C AWCUGJTVKPBYHS-CQSZACIVSA-N 0.000 claims description 6
- ZAMNYDQBNJFTSZ-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound CC1(CN)CCN(CC1)C1=CN=C(C(N)=N1)C1=CC=CC(Cl)=C1Cl ZAMNYDQBNJFTSZ-UHFFFAOYSA-N 0.000 claims description 6
- JBLYMVJAFCDNOA-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrazin-2-amine Chemical compound NCC1(CCN(CC1)C1=CN=C(C(=N1)N)SC=1C(=NC=CC1)C(F)(F)F)C JBLYMVJAFCDNOA-UHFFFAOYSA-N 0.000 claims description 6
- YFMXXMJLAJOQKJ-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-phenylpiperidin-1-yl]-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NCC1(CCN(CC1)C1=CN=C(C(N)=N1)C1=CC=CC(Cl)=C1Cl)C1=CC=CC=C1 YFMXXMJLAJOQKJ-UHFFFAOYSA-N 0.000 claims description 6
- GHNNUZAENHZAOE-SWLSCSKDSA-N 6-amino-2-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-3-methyl-5-[3-(trifluoromethyl)pyridin-4-yl]sulfanylpyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)c1nc(N)c(Sc2ccncc2C(F)(F)F)c(=O)n1C GHNNUZAENHZAOE-SWLSCSKDSA-N 0.000 claims description 6
- QZHZIDHAIVAHMD-SMDDNHRTSA-N 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-methyl-5-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C)=O)SC=1C(=NC=CC=1)C(F)(F)F QZHZIDHAIVAHMD-SMDDNHRTSA-N 0.000 claims description 6
- FWLRJXKKWWAIIU-MEDUHNTESA-N 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-[3-amino-2-(trifluoromethyl)phenyl]sulfanyl-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C)=O)SC1=C(C(=CC=C1)N)C(F)(F)F FWLRJXKKWWAIIU-MEDUHNTESA-N 0.000 claims description 6
- OOZUDBICHRCGIM-LLVKDONJSA-N 6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanyl-2-[(4R)-4-amino-2,2-difluoro-8-azaspiro[4.5]decan-8-yl]-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2(CC(C[C@H]2N)(F)F)CC1)C)=O)SC1=C(C(=NC=C1)N)Cl OOZUDBICHRCGIM-LLVKDONJSA-N 0.000 claims description 6
- NYPXMXPABWAYNI-UHFFFAOYSA-N CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4CCCCn4c3=O)c2Cl)c(N)n1 Chemical compound CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4CCCCn4c3=O)c2Cl)c(N)n1 NYPXMXPABWAYNI-UHFFFAOYSA-N 0.000 claims description 6
- JJTYMCPMKUFMGA-UHFFFAOYSA-N N-[3-[3-amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl]sulfanyl-2-chlorophenyl]-2-benzyl-3-hydroxy-1-methyl-5-oxo-2H-pyrrole-4-carboxamide Chemical compound CN1C(Cc2ccccc2)C(O)=C(C(=O)Nc2cccc(Sc3ncc(nc3N)N3CCC(C)(N)CC3)c2Cl)C1=O JJTYMCPMKUFMGA-UHFFFAOYSA-N 0.000 claims description 6
- SJVCCJDLEIGCAW-QGZVFWFLSA-N N[C@@H]1COCC11CCN(CC1)C1=NC(N)=C(SC2=CC=CC(NC(=O)C3=C(O)N=C4CCCCN4C3=O)=C2Cl)N=C1 Chemical compound N[C@@H]1COCC11CCN(CC1)C1=NC(N)=C(SC2=CC=CC(NC(=O)C3=C(O)N=C4CCCCN4C3=O)=C2Cl)N=C1 SJVCCJDLEIGCAW-QGZVFWFLSA-N 0.000 claims description 6
- ZVBSVBHUEYAOGL-UHFFFAOYSA-N Nc1nc(cnc1Sc1cccc(NC(=O)c2c(O)nc3ccccn3c2=O)c1Cl)N1CCC(N)(CF)CC1 Chemical compound Nc1nc(cnc1Sc1cccc(NC(=O)c2c(O)nc3ccccn3c2=O)c1Cl)N1CCC(N)(CF)CC1 ZVBSVBHUEYAOGL-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- VPCWGBLXOCIIMU-WCQYABFASA-N (2R,4R)-4-amino-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-2-ol Chemical compound N[C@@H]1C[C@H](O)CC11CCN(CC1)C1=CN=C(SC2=CC=NC(N)=C2Cl)C=N1 VPCWGBLXOCIIMU-WCQYABFASA-N 0.000 claims description 5
- XDODTCSHMOQQKP-GXTWGEPZSA-N (2R,4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=CN=C(SC2=CC=NC(N)=C2Cl)C=N1 XDODTCSHMOQQKP-GXTWGEPZSA-N 0.000 claims description 5
- FDSVUVZQRZMZJD-MGPLVRAMSA-N (3S,4S)-8-[3-(2,3-dichloropyridin-4-yl)-2H-pyrazolo[3,4-b]pyrazin-6-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound ClC1=NC=CC(=C1Cl)C1=NNC2=NC(=CN=C21)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1 FDSVUVZQRZMZJD-MGPLVRAMSA-N 0.000 claims description 5
- DYZZCXHBYCBNEC-CQSZACIVSA-N (4R)-8-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(CCC[C@H]2N)CC1)C1=C(C(=CC=C1)Cl)Cl DYZZCXHBYCBNEC-CQSZACIVSA-N 0.000 claims description 5
- DIFDDGZESHEIPC-JOPIAHFSSA-N (4R)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound CC1CCC2(CCN(CC2)C2=CN=C(SC3=CC=NC(N)=C3Cl)C(N)=N2)[C@@H]1N DIFDDGZESHEIPC-JOPIAHFSSA-N 0.000 claims description 5
- YXXCYOPEUVHPLV-GFCCVEGCSA-N (4R)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(CCC[C@H]2N)CC1)SC1=C(C(=NC=C1)N)Cl YXXCYOPEUVHPLV-GFCCVEGCSA-N 0.000 claims description 5
- MLZSINIGJFDNQZ-UHFFFAOYSA-N 6-(1,8-diazaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound ClC1=C(C=CC=C1Cl)C=1C(=NC(=CN=1)N1CCC2(CCCN2)CC1)N MLZSINIGJFDNQZ-UHFFFAOYSA-N 0.000 claims description 5
- PXWVEUAMAFDBCT-SWLSCSKDSA-N 6-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-3-(6-amino-2-methylpyridin-3-yl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)c1nc2n[nH]c(-c3ccc(N)nc3C)c2c(=O)n1C PXWVEUAMAFDBCT-SWLSCSKDSA-N 0.000 claims description 5
- LNQYLYAZNKGMBQ-GOEBONIOSA-N 6-amino-2-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-3-methyl-5-phenylpyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=NC(N)=C(C2=CC=CC=C2)C(=O)N1C LNQYLYAZNKGMBQ-GOEBONIOSA-N 0.000 claims description 5
- IKKUGOCAYJSNOZ-XJKSGUPXSA-N 6-amino-2-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-5-(4-chlorophenyl)-3-methylpyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=NC(N)=C(C2=CC=C(Cl)C=C2)C(=O)N1C IKKUGOCAYJSNOZ-XJKSGUPXSA-N 0.000 claims description 5
- NQCUFBIRMAZNJZ-SWLSCSKDSA-N 6-amino-2-[(3S,4S)-4-amino-3-ethyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-methyl-5-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)CC)N)CC1)C)=O)SC=1C(=NC=CC=1)C(F)(F)F NQCUFBIRMAZNJZ-SWLSCSKDSA-N 0.000 claims description 5
- DEBVNDHNGLRJKA-XHDPSFHLSA-N 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-methyl-5-[3-(trifluoromethyl)pyridin-4-yl]sulfanylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C)=O)SC1=C(C=NC=C1)C(F)(F)F DEBVNDHNGLRJKA-XHDPSFHLSA-N 0.000 claims description 5
- YDOIDJXVWAVDGD-MEDUHNTESA-N 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)sulfanyl-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C)=O)SC1=C(C(=CC=C1)Cl)Cl YDOIDJXVWAVDGD-MEDUHNTESA-N 0.000 claims description 5
- YQIKHFKYMKSZMC-YVEFUNNKSA-N 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2-chloro-3-methoxyphenyl)sulfanyl-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C)=O)SC1=C(C(=CC=C1)OC)Cl YQIKHFKYMKSZMC-YVEFUNNKSA-N 0.000 claims description 5
- SXLOCFFGRYJKJH-UHFFFAOYSA-N CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4ccccn4c3=O)c2Cl)c(N)n1 Chemical compound CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4ccccn4c3=O)c2Cl)c(N)n1 SXLOCFFGRYJKJH-UHFFFAOYSA-N 0.000 claims description 5
- JBTYRLRPDPSWAY-UHFFFAOYSA-N N-[3-[3-amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl]sulfanyl-2-chlorophenyl]-3-hydroxy-5-oxo-1-phenyl-2H-pyrrole-4-carboxamide Chemical compound CC1(N)CCN(CC1)c1cnc(Sc2cccc(NC(=O)C3=C(O)CN(C3=O)c3ccccc3)c2Cl)c(N)n1 JBTYRLRPDPSWAY-UHFFFAOYSA-N 0.000 claims description 5
- QQGWBWWGXPNCEH-UHFFFAOYSA-N NC=1C(=NC=C(N=1)N1CCC(CC1)(CF)N)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC(CC1)(CF)N)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl QQGWBWWGXPNCEH-UHFFFAOYSA-N 0.000 claims description 5
- PVBNSTQJFPASQY-QGZVFWFLSA-N NC=1C(=NC=C(N=1)N1CCC2(CC(C[C@H]2N)(F)F)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC2(CC(C[C@H]2N)(F)F)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl PVBNSTQJFPASQY-QGZVFWFLSA-N 0.000 claims description 5
- QZVSNMBRLYUYQI-GOSISDBHSA-N NC=1C(=NC=C(N=1)N1CCC2(CCC[C@H]2N)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC2(CCC[C@H]2N)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl QZVSNMBRLYUYQI-GOSISDBHSA-N 0.000 claims description 5
- NGJFCIYVFFUILZ-OYHNWAKOSA-N NC=1C(=NC=C(N=1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl NGJFCIYVFFUILZ-OYHNWAKOSA-N 0.000 claims description 5
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 126
- 238000000034 method Methods 0.000 description 115
- 150000001875 compounds Chemical class 0.000 description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 201000010099 disease Diseases 0.000 description 25
- 239000002552 dosage form Substances 0.000 description 24
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 24
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 21
- 230000002062 proliferating effect Effects 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 229950001290 lorlatinib Drugs 0.000 description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 12
- 229960001611 alectinib Drugs 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- -1 5-chloro-N2-[2-isopropoxy-5-methyl-4-(phenyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine Chemical group 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000008707 rearrangement Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000010293 colony formation assay Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- LEHJCMYPLJNJNF-UHFFFAOYSA-N 15-oxa-3,6,7,12-tetrazatricyclo[15.4.0.05,9]henicosa-1,3,5,7,9,11,13,16,18,20-decaene-8-carbonitrile Chemical compound O1C=CN=CC=C2C(C#N)=NN=C2C=NC=C2C=CC=CC2=C1 LEHJCMYPLJNJNF-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ILINPAZQNCUDMW-CYBMUJFWSA-N (4R)-8-[6-amino-5-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical group NC1=C(N=CC(=N1)N1CCC2(CCC[C@H]2N)CC1)SC=1C(=NC=CC=1)C(F)(F)F ILINPAZQNCUDMW-CYBMUJFWSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000012050 conventional carrier Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000011885 synergistic combination Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000013414 tumor xenograft model Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- HRZBBEFONKKGFY-GFCCVEGCSA-N (4S)-8-[6-amino-5-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical group NC1=C(N=CC(=N1)N1CCC2([C@@H](COC2)N)CC1)SC=1C(=NC=CC1)C(F)(F)F HRZBBEFONKKGFY-GFCCVEGCSA-N 0.000 description 3
- PMWMMYBAECEPMB-BLLLJJGKSA-N 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(3-chloro-2-methylpyridin-4-yl)sulfanyl-3-methylpyrimidin-4-one Chemical group NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C)=O)SC1=C(C(=NC=C1)C)Cl PMWMMYBAECEPMB-BLLLJJGKSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 2
- VQAQTZNNHVMDPU-UHFFFAOYSA-N 3-(3-amino-2-chlorophenyl)sulfanyl-6-chloropyrazin-2-amine Chemical compound NC=1C(=C(C=CC1)SC=1C(=NC(=CN1)Cl)N)Cl VQAQTZNNHVMDPU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 2
- 101150023956 ALK gene Proteins 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000004654 survival pathway Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- BKDDJGCNXHOTBB-UHFFFAOYSA-N tert-butyl N-[1-[6-amino-5-(3-amino-2-chlorophenyl)sulfanylpyrazin-2-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound NC1=C(N=CC(=N1)N1CCC(CC1)(C)NC(OC(C)(C)C)=O)SC1=C(C(=CC=C1)N)Cl BKDDJGCNXHOTBB-UHFFFAOYSA-N 0.000 description 2
- MNMUYHUGNVFION-UHFFFAOYSA-N tert-butyl N-[1-[6-amino-5-[2-chloro-3-[(2-hydroxy-4-oxopyrido[1,2-a]pyrimidine-3-carbonyl)amino]phenyl]sulfanylpyrazin-2-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound NC1=C(N=CC(=N1)N1CCC(CC1)(C)NC(OC(C)(C)C)=O)SC1=C(C(=CC=C1)NC(=O)C1=C(N=C2N(C1=O)C=CC=C2)O)Cl MNMUYHUGNVFION-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- CRRWKEIHCNFDBJ-UHFFFAOYSA-N 3-amino-2-chlorobenzenethiol hydron chloride Chemical compound [H+].[Cl-].Nc1cccc(S)c1Cl CRRWKEIHCNFDBJ-UHFFFAOYSA-N 0.000 description 1
- BOLCKGGORFPPJC-UHFFFAOYSA-N 3-bromo-6-chloropyrazin-2-amine Chemical compound NC1=NC(Cl)=CN=C1Br BOLCKGGORFPPJC-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- MFLTXQYKSQHVJR-UHFFFAOYSA-N 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)pyrimidine-2,4-diamine Chemical group CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)N)Cl MFLTXQYKSQHVJR-UHFFFAOYSA-N 0.000 description 1
- WAUOJBCUODZQIX-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-amine Chemical compound NC=1C=NC=C(N1)N1CCC(CC1)(C)N WAUOJBCUODZQIX-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DGFTUQSGBRDYJN-UHFFFAOYSA-N C(C)(C)OC1=C(C=C(C(=C1)C1CCNCC1)C)C1(NC=CC(=N1)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)N Chemical compound C(C)(C)OC1=C(C=C(C(=C1)C1CCNCC1)C)C1(NC=CC(=N1)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)N DGFTUQSGBRDYJN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-O bis(2-hydroxyethyl)azanium Chemical compound OCC[NH2+]CCO ZBCBWPMODOFKDW-UHFFFAOYSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- XXZMPJQRBSTHCX-UHFFFAOYSA-N methyl 2-hydroxy-4-oxopyrido[1,2-a]pyrimidine-3-carboxylate Chemical compound COC(=O)C1=C(O)N=C2C=CC=CN2C1=O XXZMPJQRBSTHCX-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HSZCJVZRHXPCIA-UHFFFAOYSA-N n-benzyl-n-ethylaniline Chemical compound C=1C=CC=CC=1N(CC)CC1=CC=CC=C1 HSZCJVZRHXPCIA-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- MVUNGZMGWJXPIM-UHFFFAOYSA-N tert-butyl n-(4-methylpiperidin-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(C)CCNCC1 MVUNGZMGWJXPIM-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022142153A JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444493P | 2017-01-10 | 2017-01-10 | |
| US62/444,493 | 2017-01-10 | ||
| PCT/IB2018/050111 WO2018130928A1 (en) | 2017-01-10 | 2018-01-08 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142153A Division JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504136A JP2020504136A (ja) | 2020-02-06 |
| JP2020504136A5 JP2020504136A5 (enExample) | 2021-02-04 |
| JP7503380B2 true JP7503380B2 (ja) | 2024-06-20 |
Family
ID=61028108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536863A Active JP7503380B2 (ja) | 2017-01-10 | 2018-01-08 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
| JP2022142153A Pending JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142153A Pending JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190343836A1 (enExample) |
| EP (1) | EP3568204B1 (enExample) |
| JP (2) | JP7503380B2 (enExample) |
| KR (1) | KR102571130B1 (enExample) |
| CN (1) | CN110730678B (enExample) |
| AU (1) | AU2018207464B2 (enExample) |
| CA (1) | CA3048340A1 (enExample) |
| ES (1) | ES2964956T3 (enExample) |
| IL (1) | IL267617A (enExample) |
| RU (1) | RU2769132C2 (enExample) |
| WO (1) | WO2018130928A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| CA3024706A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| MA45189A (fr) * | 2016-06-07 | 2019-04-10 | Jacobio Pharmaceuticals Co Ltd | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 |
| CA3023216A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| AU2018210196B2 (en) | 2017-01-23 | 2022-06-02 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| JP7447002B2 (ja) | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 |
| CA3078565A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| MX2020008754A (es) | 2018-03-02 | 2020-12-07 | Otsuka Pharma Co Ltd | Compuestos farmaceuticos. |
| MY203305A (en) | 2018-03-19 | 2024-06-23 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| CN112368272B (zh) | 2018-03-21 | 2023-04-21 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
| MA53395A (fr) * | 2018-07-24 | 2021-06-02 | Otsuka Pharma Co Ltd | Composés hétérobicycliques pour inhiber l'activité de shp2 |
| ES2981592T3 (es) | 2018-08-10 | 2024-10-09 | Navire Pharma Inc | Derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3H)-ona y compuestos relacionados como inhibidores de PTPN11 (SHP2) para tratar el cáncer |
| TWI827677B (zh) | 2018-09-18 | 2024-01-01 | 美商尼坎醫療公司 | 作為src同源-2磷酸酶抑制劑之稠合三環衍生物 |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN111153899B (zh) * | 2018-11-08 | 2023-12-01 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡啶化合物、其制备方法和用途 |
| BR112021009880A2 (pt) | 2018-11-30 | 2021-08-17 | Tuojie Biotech (Shanghai) Co., Ltd. | pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos |
| TW202045172A (zh) * | 2019-02-12 | 2020-12-16 | 瑞士商諾華公司 | 包含tno155和pd-1抑制劑之藥物組合 |
| TWI831916B (zh) * | 2019-02-12 | 2024-02-11 | 瑞士商諾華公司 | 包含tno155和瑞博西尼之藥物組合 |
| EP4249000A3 (en) * | 2019-02-12 | 2023-12-27 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| CA3130080A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| US11033547B2 (en) | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| CN113646049B (zh) | 2019-04-08 | 2024-08-13 | 默克专利有限公司 | 作为shp2拮抗剂的嘧啶酮衍生物 |
| BR112021024674A2 (pt) | 2019-06-28 | 2022-05-31 | Tuojie Biotech Shanghai Co Ltd | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| WO2021061515A1 (en) * | 2019-09-23 | 2021-04-01 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
| CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
| KR20250175006A (ko) | 2019-11-04 | 2025-12-15 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| WO2021110796A1 (en) * | 2019-12-04 | 2021-06-10 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| CN113135910A (zh) * | 2020-01-19 | 2021-07-20 | 北京诺诚健华医药科技有限公司 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
| TW202140024A (zh) * | 2020-01-24 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | Shp2抑制劑嘧啶酮與新穎癌症醫藥併用於癌症之抗腫瘤活性之增強 |
| CN111265529B (zh) * | 2020-02-22 | 2021-07-23 | 南京大学 | 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用 |
| CN111393459B (zh) * | 2020-04-16 | 2022-07-22 | 南京安纳康生物科技有限公司 | Shp2抑制剂及其用途 |
| CA3179994A1 (en) * | 2020-05-08 | 2021-11-11 | Novartis Ag | Pharmaceutical combination comprising tno155 and nazartinib |
| WO2021236775A1 (en) * | 2020-05-19 | 2021-11-25 | The Regents Of The University Ofmichigan | Small molecule degraders of shp2 protein |
| EP4165033A4 (en) * | 2020-06-11 | 2024-10-23 | Betta Pharmaceuticals Co., Ltd | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF |
| MX2022016355A (es) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. |
| CN115667239B (zh) * | 2020-06-22 | 2025-11-18 | 四川科伦博泰生物医药股份有限公司 | 取代吡嗪类化合物，包含其的药物组合物及其用途 |
| WO2022009098A1 (en) | 2020-07-08 | 2022-01-13 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
| KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CN114437116B (zh) * | 2020-10-30 | 2025-12-19 | 赣江新区博瑞创新医药有限公司 | 杂环化合物及其制备方法、药物组合物和应用 |
| CN112194652B (zh) * | 2020-11-30 | 2021-03-05 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物、制备方法及应用 |
| CN112402385B (zh) * | 2020-11-30 | 2022-04-01 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法 |
| CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| CA3217084A1 (en) | 2021-05-05 | 2022-11-10 | Farbod Shojaei | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL308225A (en) * | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| EP4333850A4 (en) | 2021-05-05 | 2025-04-09 | Huyabio International, LLC | SHP2 INHIBITOR MONOTHERAPY AND ITS USES |
| TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技（上海）有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
| CA3224155A1 (en) * | 2021-07-07 | 2023-01-12 | Lei Fan | Synthesis and application of phosphatase degrader |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20230106506A (ko) * | 2022-01-03 | 2023-07-13 | 한국생명공학연구원 | Cda 억제제를 포함하는 alk 저해제 내성 비소세포폐암 치료용 조성물 |
| TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| CN120227378A (zh) * | 2023-12-28 | 2025-07-01 | 轩竹生物科技股份有限公司 | 间变性淋巴瘤激酶抑制剂的药物组合物及其制备方法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| US4959368A (en) | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| DK169008B1 (da) | 1990-06-01 | 1994-07-25 | Holec Lk A S | Fremgangsmåde og skærm til afskærmning af en strømtransformer samt strømtransformer med en sådan afskærmning |
| GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| WO2000059893A1 (en) | 1999-04-06 | 2000-10-12 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| EP1438053B1 (de) | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| GB0300783D0 (en) | 2003-01-14 | 2003-02-12 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| CA2562126A1 (en) | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| RU2423351C2 (ru) | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
| AU2006290715A1 (en) | 2005-09-13 | 2007-03-22 | Palau Pharma, S.A. | 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity |
| JP2009531456A (ja) | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | （ｒ）−３−アミノピペリジン二塩酸塩の調製 |
| US7515405B2 (en) | 2006-07-25 | 2009-04-07 | Hewlett-Packard Development Company, L.P. | Anti-rotation mechanism for an electronic device |
| US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| PT2091918E (pt) | 2006-12-08 | 2014-11-24 | Irm Llc | Compostos e composições como inibidores de proteína cinase |
| EP2120573A4 (en) | 2007-02-12 | 2011-05-25 | Merck Sharp & Dohme | piperidine |
| KR101473504B1 (ko) | 2007-03-15 | 2014-12-16 | 노파르티스 아게 | 유기 화합물 및 그의 용도 |
| BRPI0910668A2 (pt) | 2008-04-22 | 2019-09-24 | Portola Pharmaceutiacals Inc | inibidores de proteína quinases |
| WO2009150230A1 (en) | 2008-06-13 | 2009-12-17 | Novartis Ag | 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer |
| MX2010013876A (es) | 2008-06-20 | 2011-03-04 | Metabolex Inc | Agonistas de arilo grpr119 y sus usos . |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2012511567A (ja) | 2008-12-10 | 2012-05-24 | ドン ファ ファーム カンパニー リミテッド | 新規の２，６−置換−３−ニトロピリジン誘導体、その製造方法及びこれを含む薬学組成物 |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| BR112012003637A2 (pt) | 2009-08-17 | 2017-04-25 | Memorial Sloan Kettering Cancer Center | "compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos" |
| US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| BR112012033770A2 (pt) | 2010-06-30 | 2016-11-22 | Fujifilm Corp | novo derivado de nicotinamida ou sal do mesmo |
| WO2012009217A1 (en) | 2010-07-13 | 2012-01-19 | Merck Sharp & Dohme Corp. | Spirocyclic compounds |
| CA2806341C (en) | 2010-07-29 | 2020-03-24 | Rigel Pharmaceuticals, Inc. | Ampk-activating heterocyclic compounds and methods for using the same |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| US9056865B2 (en) | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2-derivatives as smoothened receptor modulators |
| KR101992505B1 (ko) | 2011-09-12 | 2019-06-24 | 메르크 파텐트 게엠베하 | 키나아제 활성의 조절제로서 용도를 위한 아미노피리미딘 유도체 |
| WO2013096093A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Compounds as dgat-1 inhibitors |
| EP3333166B1 (en) | 2012-05-23 | 2019-11-06 | Nerviano Medical Sciences S.R.L. | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| MX2014014582A (es) | 2012-06-07 | 2015-05-11 | Hoffmann La Roche | Inhibidores pirazolopirimidona y pirazolopiridona de tanquirasa. |
| WO2014054053A1 (en) | 2012-10-03 | 2014-04-10 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2015050344A1 (ko) | 2013-10-01 | 2015-04-09 | 주식회사 엘지화학 | 도전성 적층체 |
| WO2015092819A2 (en) | 2013-12-21 | 2015-06-25 | Nektar Therapeutics (India) Pvt. Ltd. | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine |
| RU2016129953A (ru) * | 2013-12-23 | 2018-01-30 | Новартис Аг | Фармацевтические комбинации |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| EA036672B8 (ru) | 2014-05-01 | 2021-01-13 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической деметилазы-1 |
| US10174032B2 (en) | 2014-05-05 | 2019-01-08 | Signalrx Pharmaceuticals, Inc. | Heterocyclic compound classes for signaling modulation |
| CN107207524B (zh) | 2014-08-15 | 2020-02-07 | 贵州省中国科学院天然产物化学重点实验室 | 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途 |
| EP3185866A1 (en) * | 2014-08-25 | 2017-07-05 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| US9296721B1 (en) * | 2015-02-13 | 2016-03-29 | Yong Xu | Method for preparing ALK inhibitor ceritinib |
| EP3310774B1 (en) | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| CA3023216A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| US11529347B2 (en) * | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) * | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
-
2018
- 2018-01-08 RU RU2019120986A patent/RU2769132C2/ru active
- 2018-01-08 KR KR1020197019305A patent/KR102571130B1/ko active Active
- 2018-01-08 AU AU2018207464A patent/AU2018207464B2/en not_active Ceased
- 2018-01-08 WO PCT/IB2018/050111 patent/WO2018130928A1/en not_active Ceased
- 2018-01-08 JP JP2019536863A patent/JP7503380B2/ja active Active
- 2018-01-08 ES ES18701574T patent/ES2964956T3/es active Active
- 2018-01-08 CA CA3048340A patent/CA3048340A1/en active Pending
- 2018-01-08 CN CN201880006104.XA patent/CN110730678B/zh active Active
- 2018-01-08 EP EP18701574.8A patent/EP3568204B1/en active Active
- 2018-01-08 US US16/475,982 patent/US20190343836A1/en not_active Abandoned
-
2019
- 2019-06-24 IL IL267617A patent/IL267617A/en unknown
-
2022
- 2022-04-06 US US17/714,996 patent/US12053470B2/en active Active
- 2022-09-07 JP JP2022142153A patent/JP2022184886A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
Non-Patent Citations (1)
| Title |
|---|
| ジカディアカプセル１５０ｍｇ，医薬品インタビューフォーム，第１版，ノバルティスファーマ株式会社，２０１６年 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102571130B1 (ko) | 2023-08-28 |
| US20220241277A1 (en) | 2022-08-04 |
| EP3568204A1 (en) | 2019-11-20 |
| RU2769132C2 (ru) | 2022-03-28 |
| WO2018130928A1 (en) | 2018-07-19 |
| RU2019120986A (ru) | 2021-02-12 |
| AU2018207464B2 (en) | 2020-05-14 |
| KR20190104530A (ko) | 2019-09-10 |
| IL267617A (en) | 2019-08-29 |
| CN110730678A (zh) | 2020-01-24 |
| JP2020504136A (ja) | 2020-02-06 |
| ES2964956T3 (es) | 2024-04-10 |
| CN110730678B (zh) | 2022-07-15 |
| JP2022184886A (ja) | 2022-12-13 |
| CA3048340A1 (en) | 2018-07-19 |
| US20190343836A1 (en) | 2019-11-14 |
| RU2019120986A3 (enExample) | 2021-03-19 |
| AU2018207464A1 (en) | 2019-06-20 |
| EP3568204B1 (en) | 2023-08-30 |
| US12053470B2 (en) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7503380B2 (ja) | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 | |
| JP7617076B2 (ja) | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 | |
| US20230158022A1 (en) | Methods of using myt1 inhibitors | |
| JP6863970B2 (ja) | ヘテロ環式化合物およびそれらの使用 | |
| US20230122909A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | |
| US9771369B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| US10130629B2 (en) | Pharmaceutical combinations | |
| US20160074409A1 (en) | Treatment of Skeletal-Related Disorders | |
| IL296934A (en) | Compounds, pharmaceutical compounds, and methods for preparing compounds and using them | |
| TWI839690B (zh) | 治療黑色素瘤的藥物組合的用途 | |
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| UA125216C2 (uk) | Комбінована терапія | |
| EA017952B1 (ru) | ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ | |
| JP6814730B2 (ja) | 治療用化合物およびその使用 | |
| JP7642556B2 (ja) | 併用医薬 | |
| HK40010171A (en) | Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor | |
| HK40010171B (en) | Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor | |
| MX2008000897A (es) | Combinacion de una pirimidil-amino-benzamida y un inhibidor de cinasa mtor. | |
| HK1247193B (zh) | 噠嗪酮衍生物及其在治療癌症中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220224 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220510 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220907 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220907 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220920 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221021 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221025 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221111 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240610 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7503380 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |